BLTE (Belite Bio) Common Stock : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Common Stock?

Belite Bio's quarterly common stock declined from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil) but then stayed the same from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil).

Belite Bio's annual common stock increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Belite Bio Common Stock Historical Data

The historical data trend for Belite Bio's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Common Stock Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Common Stock

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Common Stock	Get a 7-Day Free Trial								-	-	-	-	-

Belite Bio Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Belite Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

D01:Germany

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.